Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/4632
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Claxton, K | - |
dc.contributor.author | Briggs, AH | - |
dc.contributor.author | Buxton, MJ | - |
dc.contributor.author | Culyer, AJ | - |
dc.contributor.author | McCabe, C | - |
dc.contributor.author | Walker, S | - |
dc.contributor.author | Sculpher, MJ | - |
dc.date.accessioned | 2010-12-06T12:43:33Z | - |
dc.date.available | 2010-12-06T12:43:33Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | BMJ 336(7638): 251-254, Feb 2008 | en_US |
dc.identifier.issn | 0959-8138 | - |
dc.identifier.uri | http://www.bmj.com/content/336/7638/251 | en |
dc.identifier.uri | http://bura.brunel.ac.uk/handle/2438/4632 | - |
dc.description | The official puclished version of the article can be found at the link below | en_US |
dc.description.abstract | The policy debate about price, value, and innovation in pharmaceuticals is at a critical stage for the NHS. Karl Claxton and colleagues describe the key principles of value based pricing and consider some of the concerns about such a scheme | en_US |
dc.language.iso | en | en_US |
dc.publisher | British Medical Journal | en_US |
dc.relation.ispartof | The Health Economics Research Group | - |
dc.title | Value based pricing for NHS drugs: An opportunity not to be missed? | en_US |
dc.type | Article | en_US |
dc.identifier.doi | http://dx.doi.org/10.1136/bmj.39434.500185.25 | - |
Appears in Collections: | Health Economics Research Group (HERG) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Fulltext.pdf | 427.65 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.